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Abstract
Testicular germ cell tumour (TGCT) is the most common cancer in young men. Multiplex TGCT families
have been well reported and analyses of population cancer registries have demonstrated a four- to
eightfold risk to male relatives of TGCT patients. Early linkage analysis and recent large-scale germline
exome analysis in TGCT cases demonstrate absence of major high-penetrance TGCT susceptibility gene
(s). Serial genome-wide association study analyses in sporadic TGCT have in total reported 49 inde-
pendent risk loci. To date, it has not been demonstrated whether familial TGCT arises due to
enrichment of the same common variants underpinning susceptibility to sporadic TGCT or is due
to shared environmental/lifestyle factors or disparate rare genetic TGCT susceptibility factors. Here we
present polygenic risk score analysis of 37 TGCT susceptibility single-nucleotide polymorphisms in
236 familial and 3931 sporadic TGCT cases, and 12 368 controls, which demonstrates clear enrichment
for TGCT susceptibility alleles in familial compared to sporadic cases (p = 0.0001), with the majority of
familial cases (84–100%) being attributable to polygenic enrichment. These analyses reveal TGCT as the
ﬁrst rare malignancy of early adulthood in which familial clustering is driven by the aggregate effects of
polygenic variation in the absence of a major high-penetrance susceptibility gene.
Patient summary: To date, it has been unclear whether familial clusters of testicular germ cell
tumour (TGCT) arise due to genetics or shared environmental or lifestyle factors. We present large-
scale genetic analyses comparing 236 familial TGCT cases, 3931 isolated TGCT cases, and 12
368 controls. We show that familial TGCT is caused, at least in part, by presence of a higher dose
of the same common genetic variants that cause susceptibility to TGCT in general.
© 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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\Testicular germ cell tumour (TGCT) is the most common
cancer in young men, with over 18 000 new cases of TGCT
diagnosed annually in Europe [1]. Over the past 40 yr,
several authors have reported families with multiple cases
of TGCT. Such observations, coupled with the higher
concordance of TGCT in monozygotic twins than in
dizygotic twins have suggested a heritable basis to TGCT
[2]. In the 2000s, systematic family studies, including in
population-based registries, confirmed that first-degree
relatives of patients with TGCT, have four- to eight-fold
higher risk for TGCT. Based on data from the Swedish
nationwide registry, around 2% of TGCT cases have a first-
degree relative with TGCT [3]. Whilst the clustering of TGCT
in families has raised the possibility of Mendelian suscepti-
bility, linkage analyses and large-scale exome sequencing of
familial TGCT have not provided evidence for high-
penetrance susceptibility genes [4–6].
Meanwhile, recent genome-wide association studies
(GWAS) have identified single-nucleotide polymorphisms
(SNPs) at 49 independent loci associated with TGCT risk
[7,8]. While the identification of such risk alleles proves the
existence of inherited susceptibility, the genetic basis of
familial TGCT is unclear. The identified risk SNPs are
common, have modest effects, and have been discovered by
comparing unselected cases with controls. Although
statistical predictions suggest that common susceptibility
may account for around 37% of the familial risk [7,8], thus far
no direct evidence for such a polygenic aetiology has been
reported. Whilst the rapid doubling of TGCT incidence over
the past 40 yr has been taken as evidence for significant
environmental influences on TGCT aetiology, no specific
environmental risk factors have been robustly established
[1,9]. Therefore, it is an open question as to whether familial
TGCT is a consequence of the co-existence of unusually high
numbers of common risk alleles or arises due to other rarer
genetic factors, shared environmental exposure, or common
lifestyle factors.
To explore the role of polygenic susceptibility in the
aetiology of familial TGCT, we studied 236 familial and
3931 sporadic TGCT cases, and 12 368 healthy population
controls derived from two previously published GWAS (see
Supplementary materials). Briefly, cases and controls were
genotyped using illumina arrays with recovery of untyped
genotypes by imputation. Both cases and controls were of
European ancestry. We extracted the genotypes of tag SNPs
for 37 risk loci (Supplementary Table 2) which have been
robustly associated with TGCT and for which high-quality
direct or imputed genotypes were available for both GWAS
datasets. We quantified risk allele burden using two
approaches. First, we calculated the total number of risk
Fig. 1 – Testicular germ cell tumour (TGCT) risk alleles in TGCT cases and controls. Polygenic risk scores are plotted to show (A) probability density
function (PDF) and (B) cumulative distribution function (CDF) for familial TGCT (green, n = 236), sporadic TGCT (blue, n = 3931), and controls (red,
n = 12,368). PDF and CDF are also shown for risk allele counts, unweighted by effect size, in (C) and (D), respectively.
PRS = polygenic risk score; TGCT = testicular germ cell tumour.
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alleles and second, we calculated a polygenic risk score
(PRS) combining the number of risk alleles weighted by
their effect size. To avoid statistical inflation resulting from
the analysis of multiple related family members, we only
included a single affected proband from each of the
236 multiplex TGCT families (Supplementary Table 1).
Comparing the different groups, we observed a signifi-
cant enrichment of risk alleles in familial cases compared
with sporadic cases (average number of risk alleles,
p = 0.0001; average PRS, p = 0.0001; Fig. 1; Supplementary
Table 3). Notably, these differences were seen in each of the
contributing GWAS datasets (Supplementary Figs. 1 and 2).
The most overrepresented risk allele in familial compared to
sporadic cases was SNP rs3751673 (chromosome 16q24.2;
risk allele frequency, 0.75 vs 0.65, respectively; Cochran-
Armitage trend test, p = 0.006; Bonferroni-corrected,
p = 0.22; Supplementary Table 4).
We next examined the relationship between PRS and
familial TGCT in more detail. Although not statistically
significant, likely on account of the limited number of
“large” families available for analysis, PRS was found to be
greater in probands from families with three or more cases
of TGCT compared with two-case TGCT families (Supple-
mentary Fig. 3). Familial relative risks for TGCT have been
reported in epidemiological studies to be higher for
brothers than in father–son TGCT families [3]; however,
we found no significant difference in PRS between familial
cases analyzed by pedigree structure (Supplementary Fig.
3). To better quantify the extent of disease within each
family and take account of bilateral disease, we generated a
family history score that incorporates the number of
affected individuals, degree of relatedness, and the occur-
rence of bilateral disease (see Supplementary materials).
PRS was positively correlated with this family history score,
albeit again not reaching statistical significance (p = 0.09,
Fig. 2). Collectively, these results provide strong evidence
for enrichment for known common TGCT risk alleles
underpinning familial clustering of TGCT.
We next estimated the proportion of familial TGCT that is
attributable to enrichment of common risk alleles adopting
the strategy of Halvarsson et al [9], which is based on the
premise that, theoretically, a PRS can be drawn from one of
two distributions depending on aetiology. Cases caused
by enrichment of common TGCT risk alleles will follow a
Fig. 2 – Relationship between ranked polygenic risk score and family history score. Spearman rank correlation showing the relationship between
ranked polygenic risk score (y-axis) and ranked family history score (x-axis) for the 228 familial testicular germ cell tumour cases with a known
pedigree structure. The underlying distributions of those data are shown, respectively, on the opposite axes.
Rho = 0.09; p = 0.09.
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right-shifted risk score distribution, whereas cases caused
by other factors (not reflected in PRS) will follow the same
distribution as the population. To estimate the relative
proportion of the two underlying distributions, we fitted a
two-component Gaussian mixture model to the observed
PRS for familial TGCT cases, restricting one component of
the model to the distribution parameters defined by
controls. The proportion of familial TGCT following a
right-shifted distribution (ie, enriched for TGCT suscepti-
bility alleles) in our dataset was 100%, with the lower bound
of this estimate at 84% (Supplementary Table 5). Similar
results were obtained when using the number of risk alleles,
unweighted by effect size (98%, 95% confidence interval [CI]:
54–100%; Supplementary Table 5). Together, these results
indicate attribution to enrichment for common TGCT risk
alleles for the majority of TGCT families analyzed.
Survival from TGCT is high; however, the success of
treatment is accompanied by long-term consequences
associated with survivorship. TGCT is a model of disease
in which prediction and early intervention could be
impactful, as the precursor carcinoma-in-situ (CIS) lesion
is reliably present from adolescence, with CIS cells
exfoliated in the semen [10]. Early intervention could
reduce the occurrence of invasive cancer arising in young
men, reducing the burden of chemotherapy-related survi-
vorship issues and reducing mortality in the minority with
treatment-refractory disease state. Therefore, whilst un-
derstanding the inherited basis of TGCT is useful for
counseling of individuals concerned about a family history
of the disease, such information may also be important for
TGCT-screening programs targeting those at elevated a
priori risk.
In conclusion, we present the first evidence of clear
enrichment in familial TGCT for common TGCT susceptibili-
ty alleles, demonstrating that familial clustering of TGCT is
at least in part due to enrichment for the same genetic
factors that confer susceptibility to sporadic TGCT. We
demonstrate attribution to polygenic susceptibility in the
majority of TGCT families. The enrichment of common TGCT
risk alleles among familial cases is sufficiently modest in
magnitude that existence of additional genetic and envi-
ronmental drivers of familial TGCT remains possible. Future
studies will provide further elucidation of the genetic basis
of familial TGCT and empower clinical application.
Declarations
Ethics approval and consent to participate: Collection of blood samples
and clinical information from patients was undertaken with informed
written consent and relevant ethical review board approval at respective
institutions.
Consent for publication: No identiﬁable persons’ data was used in this
study.
Availability of data and materials: Case OncoArrray GWAS data and case/
control UK Phase I GWAS data have been deposited in the European
Genome–phenome Archive (EGA) under accession codes
EGAS00001001836 and EGAS00001001302, respectively.
Author contributions: Clare Ann Turnbull had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Turnbull, Houlston, Law, Loveday.
Acquisition of data: Levy, Dudakia, Holroyd, Broderick, Jarai, Dunning,
Muir, Peto, Eeles, Easton, Orr, Reid, Huddart.
Analysis and interpretation of data: Turnbull, Houlston, Litchﬁeld,
Loveday.
Drafting of the manuscript: Turnbull, Loveday.
Critical revision of the manuscript for important intellectual content:
Turnbull, Houlston, Loveday.
Statistical analysis: Loveday, Law, Litchﬁeld, Levy.
Obtaining funding: Turnbull.
Administrative, technical, or material support: Levy, Broderick, Dudakia.
Supervision: None.
Other (specify): None.
Financial disclosures: Clare Ann Turnbull certiﬁes that all conﬂicts of
interest, including speciﬁc ﬁnancial interests and relationships and
afﬁliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/afﬁliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents ﬁled, received, or pending), are the following: None.
Funding/Support and role of the sponsor: This study was supported by
the Movember foundation and the Institute of Cancer Research. K.
Litchﬁeld was supported by a PhD Studentship from Cancer Research UK.
Richard S. Houlston and Peter Broderick are supported by Cancer
Research UK.
Genotyping of the OncoArray was funded by the US National Institutes of
Health (NIH) (U19 CA 148537 for ELucidating Loci Involved in Prostate
cancer SuscEptibility project and X01HG007492 to the Center for
Inherited Disease Research under contract number
HHSN268201200008I). Additional analytic support was provided by
NIH NCI U01 CA188392 (PI: Schumacher).
The PRACTICAL consortium was supported by Cancer Research UK Grants
C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/
A10692, C16913/A6135, European Commission's Seventh Framework
Programme grant agreement n 223175 (HEALTH-F2-2009-223175), and
The National Institute of Health (NIH) Cancer Post-Cancer GWAS
initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).
Acknowledgments: We thank the patients with TGCT and the clinicians
involved in their care for participation in this study. We thank the
patients and all clinicians forming part of the UK Testicular Cancer
Collaboration for their participation in this study. This study would not
have been possible without the contributions of M.K. Bolla (Breast
Cancer Association Consortium [BCAC]), Q. Wang (BCAC), K. Michailido
(BCAC), J. Dennis (BCAC), P. Hall (Collaborative Oncological Gene-
environment Study [COGS]), D.F. Easton (BCAC), A. Berchuck (Ovarian
Cancer Association Consortium), R. Eeles (PRACTICAL), G. Chenevix-
Trench (The Consortium of Investigators of Modiﬁers of BRCA1/2), J.
Dennis, P. Pharoah, A. Dunning, K. Muir, J. Peto, A. Lee, and E. Dicks. We
also thank the following for their contributions to this project: J. Simard,
P. Kraft, C. Luccarini, and the staff of the Centre for Genetic Epidemiology
Laboratory; and K.F. Doheny and the staff of the Center for Inherited
Disease Research (CIDR) genotyping facility. The results published here
are based in part on data generated by the TCGA Research Network. This
study makes use of data generated by the Wellcome Trust Case Control
Consortium 2.
We would also like to thank the following for funding support: The
Institute of Cancer Research and The Everyman Campaign, The Prostate
Cancer Research Foundation, Prostate Research Campaign UK (now
Prostate Action), The Orchid Cancer Appeal, The National Cancer
Research Network UK, and The National Cancer Research Institute UK.
E U R O P E A N U R O L O G Y X X X ( 2 0 18 ) X X X – X X X4
EURURO-7873; No. of Pages 5
Please cite this article in press as: Loveday C, et al. Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic
Aetiology. Eur Urol (2018), https://doi.org/10.1016/j.eururo.2018.05.036
We are grateful for support of NIHR funding to the NIHR Biomedical
Research Centre at The Institute of Cancer Research and The Royal
Marsden NHS Foundation Trust.
We thank all the individuals who took part in these studies and all the
researchers, clinicians, technicians, and administrative staff who have
enabled this work to be carried out.
Appendix A. Supplementary data
Supplementary material related to this article can be
found, in the online version, at https://doi.org/10.1016/j.
eururo.2018.05.036.
References
[1] Le Cornet C, Lortet-Tieulent J, Forman D, et al. Testicular cancer
incidence to rise by 25% by 2025 in Europe? Model-based predic-
tions in 40 countries using population-based registry data. Eur J
Cancer 2014;50:831–9.
[2] Swerdlow AJ, De Stavola BL, Swanwick MA, Maconochie NE. Risks of
breast and testicular cancers in young adult twins in England and
Wales: evidence on prenatal and genetic aetiology. Lancet
1997;350:1723–8.
[3] Hemminki K, Chen B. Familial risks in testicular cancer as aetiolo-
gical clues. Int J Androl 2006;1:205–10.
[4] Litchﬁeld K, Levy M, Dudakia D, et al. Rare disruptive mutations in
ciliary function genes contribute to testicular cancer susceptibility.
Nat Commun 2016;7:13840.
[5] Litchﬁeld K, Loveday C, Levy M, et al. Large-scale sequencing of
testicular germ cell tumour (TGCT) cases excludes major TGCT
predisposition gene. Eur Urol 2018;73:828–31.
[6] Stone L. No major predisposition gene in TGCT. Nat Rev Urol
2018;15:202.
[7] Litchﬁeld K, Levy M, Orlando G, et al. Identiﬁcation of 19 new risk
loci and potential regulatory mechanisms inﬂuencing susceptibility
to testicular germ cell tumor. Nat Genet 2017;49:1133–40.
[8] Wang Z, McGlynn KA, Rajpert-De Meyts E, et al. Meta-analysis of
ﬁve genome-wide association studies identiﬁes multiple new loci
associated with testicular germ cell tumor. Nat Genet
2017;49:1141–7.
[9] Halvarsson BM, Wihlborg AK, Ali M, et al. Direct evidence for a
polygenic etiology in familial multiple myeloma. Blood Adv
2017;1:619–23.
[10] Litchﬁeld K, Levy M, Huddart RA, Shipley J, Turnbull C. The genomic
landscape of testicular germ cell tumours: from susceptibility to
treatment. Nat Rev Urol 2016;13:409–19.
E U R O P E A N U R O L O G Y X X X ( 2 0 18 ) X X X – X X X 5
EURURO-7873; No. of Pages 5
Please cite this article in press as: Loveday C, et al. Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic
Aetiology. Eur Urol (2018), https://doi.org/10.1016/j.eururo.2018.05.036
